Renaissance Capital logo

OPT News

US IPO Week Ahead: Biotechs break the post-election ice in a 3 IPO week

INAB

Updated Monday, 11/9. The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead. Oncology biotech IN8bio (INAB) plans to raise $75...read more

US IPO Weekly Recap: Solar technology shines in a 9 IPO week

ARRY

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. ...read more

Australian retinal disease biotech Opthea prices US IPO at $13.50

Opthea logo

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, raised $128 million by offering 9.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on the ASX (OPT). The ADS equivalents offered consisted of 8.6...read more

US IPO Week Ahead: Healthcare, solar panels, and Chinese retail in a 9 IPO week

MCFE

Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead. Several companies could join the IPO calendar early in the week, including leading cybersecurity...read more